This study compared postoperative analgesic dispensation and measures relating to haemostasis following intravenous administration, in a randomized double-blinded manner, of either placebo or tenoxicam 20 mg to 30 women presenting for major gynaecological oncology surgery under a standardized, combined epidural/general anaesthetic technique. Pharmacokinetic disposition of tenoxicam in this patient cohort was also described. There was no objective or subjective alteration in haemostatic function or increase in blood loss, nor any deviation from the normal range of values. Postoperative analgesia during the first 48 hours was delivered to achieve a VAS endpoint of less than five on leg-raising, by a combination of a nurse-controlled low-dose background epidural infusion and patient-administered epidural bolus. Greater VAS variability was observed during the first four postoperative hours (P=0.08). The tenoxicam group self-administered significantly fewer epidural bolus doses to maintain satisfactory analgesia compared with the placebo group during the first 24 hours (P=0.004) and 48 hours (P=0.01) postoperatively. Similar differences between the groups in the total dose of the epidural bupivacaine/fentanyl mixture delivered were described (4 h: P=0.148; 24 h: P=0.033; 48 h: P=0.001) (Figure 2) . Despite surgery, transfusion and the use of a renal protective fluid administration strategy, tenoxicam disposition was not greatly different from that widely described for healthy volunteers. There were no significant side-effects and no adverse events attributable to tenoxicam. In this small study we have shown that tenoxicam administered preoperatively reduced the epidural analgesic requirements during the first 48 hours following major gynaecological surgery. There was no clinical or pathological evidence of haematological impairment following a single IV administration of tenoxicam 20 mg.
The newer non-steroidal anti-inflammatory drugs (NSAIDs) are effective analgesic agents 1 and when administered concurrently with opioids after orthopaedic surgery are opioid-sparing 2,3 , possibly reducing unwanted drug effects 4 . Tenoxicam is an NSAID which belongs to the oxicam class of compounds. The drug is completely absorbed after oral administration, is 99% protein bound, has a low volume of distribution, low systemic clearance, an average elimination half-life of approximately three days and is completely metabolized to inactive metabolites excreted in the urine and faeces 5 . Tenoxicam has potent analgesic and antiinflammatory actions which are in part mediated by its ability to inhibit cyclooxygenase and subsequent prostaglandin formation 4 which also inhibits the secondary phase of platelet aggregation. This property may be useful in major gynaecological surgery because of the associated propensity for thromboembolic phenomena 6 , providing that clinical haemostasis is not disturbed. Tenoxicam has been well studied in the treatment of rheumatic disorders 7 but there have been relatively few descriptions of its disposition after major surgery or use in the treatment of postoperative pain [8] [9] [10] [11] .
The evidence for the opioid-sparing effects of NSAID use in postoperative analgesia is often contradictory and difficult to interpret, due to highly variable and often inadequate study designs 12 and the contribution per se to the "pain syndrome" by opioid side-effects such as nausea and vomiting 13. This study is designed to test whether a single preoperative IV dose of tenoxicam is epidural dose-sparing in the acute postoperative phase, without increasing perioperative blood loss, in an elderly population subjected to a renal protection strategy. A secondary aim of the study was to examine the pharmacokinetics of tenoxicam in women undergoing major gynaecological surgery for cancer.
MATERIALS AND METHODS
Thirty patients aged 50 to 70 years undergoing laparotomy for ovarian, uterine or cervical cancer were enrolled prospectively to participate in a study approved by the Royal Women's Hospital Ethics Committee. Each patient received a verbal and plain language written description of the research protocol and all gave written consent. Patients unable to give a valid consent, or who had renal or hepatic impairment (defined for this study as any routinely measured preoperative biochemical value which fell outside the normal range published by our laboratory), bleeding diathesis, hypersensitivity to NSAIDs, asthma or requiring medication known to interfere with tenoxicam disposition were excluded. Roche Pharmaceuticals coded and randomized 30 patients using random number tables to receive either tenoxicam 20 mg diluted in 2 ml or normal saline 2 ml with vitamin B complex as colouring (prepared by Roche Pharmaceuticals (Basle, Switzerland)). The tenoxicam allocation code was not released until the end of clinical data collection and therefore all investigators, pain assessment anaesthetists, nurses and surgeons were blinded to treatment. There were no exclusions from the original data set.
On the day prior to surgery, baseline clinical chemistry, haematological function and skinfold were measured (John Bull, British Indicators Limited, England) 14 . Also on the day preceding surgery, a bowel preparation regimen of clear fluids, parenteral nutrition (Ensure, Abbott Australasia, Sydney, N.S.W.) magnesium citrate, docusate sodium and colonoscopy preparation solution was followed. Dalteparin sodium 5000 units (Pharmacia & Upjohn, Bridgewater, NJ, U.S.A.) was injected subcutaneously on the evening prior to surgery. Four hours before the anticipated surgery, urine collection was initiated after insertion of an indwelling urinary catheter and an IV infusion of 0.9% saline (10 ml.kg -1 ) was commenced via a 16 gauge cannula inserted into the cephalic vein to complete in 60 minutes and then slowed to a rate which maintained IV patency until the start of surgery. Two hours prior to the commencement of surgery a 22 gauge radial arterial cannula was inserted with local anaesthetic infiltration and samples for baseline pharmacokinetic, renal chemistry and haematological function were obtained. Pharmacokinetic samples were obtained via the arterial cannula for the first 24 hours and thereafter by venipuncture. Temazepam 0.2 mg.kg -1 was administered orally, followed by intravenous administration of the blinded preparation via the cephalic vein cannula. Venous blood samples (5 ml) for tenoxicam assay were collected into heparinized tubes at the following times: 2, 4, 8, 10, 15, 20, 30, 45, 60, 90 and 180 min and 6, 9, 24, 48, 72 and 96 hours. The plasma was separated and stored frozen at -20°C until analysis.
HPLC Assay and Pharmacokinetic Analysis
Tenoxicam concentrations in plasma were determined using a high-performance liquid chromatography (HPLC) method 15 . The liquid chromatographic system consisted of a Waters M510 pump, a Waters WISP 717 auto injector, a Waters 486 tunable absorbance UV detector interfaced to a Waters MAX810 HPLC system workstation (Waters Corporation, Milford, MA, U.S.A.). Analyses were performed on a C18 reversed phase Nova Pak Cartridge column (4 µm, 100 mm x 8 mm ID) protected by a C18 guard column. The wavelength was set at 355 nm. Plasma (1 ml) containing tenoxicam along with 100 µl of internal standard piroxicam (200 ng), was acidified with 1 ml of 1 M hydrochloric acid and 1 ml of deionized water, then extracted into 5 ml of dichloromethane in a glass tube. The mixture was then placed on a blood cell mixer for 15 minutes at 45 rpm. After centrifugation for 10 minutes at 3000 rpm, the organic phase was evaporated to dryness under a gentle stream of nitrogen. The dry residue was redissolved in 100 µl of mobile phase and an aliquot of 40 µl was injected onto the HPLC system for analysis. The mobile phase consisted of a 3:2 (v/v) mixture of phosphate buffer (0.1M, pH 7.4) and methanol, with the flow rate set at 1.1 ml.min -1 . A range of external standards (serum with known concentrations of tenoxicam and piroxicam) were measured at the beginning and end of each run of 25 samples. Each sample run took 15 minutes with tenoxicam appearing at 7.9 minutes and the internal standard at 10.5 minutes. The calibration curves were linear over the range of 20 to 2500 ng.ml -1 with coefficients of variation ranging from 0.8 to 3.2%. The limit of detection was approximately 10 ng.ml -1 . Plasma concentration-time profiles for tenoxicam were analysed using a combination of Microsoft Excel 5.0 (Microsoft, Redmond, CA) and a non-linear regression analysis program (Sigmaplot 4.11, Jandel, Corte Madera, CA), whereby each curve was fitted to the experimental data in terms of a bi-exponential or tri-exponential function 16 . Distribution and elimination half-lives (t 1/2 α, t 1/2 β), intercompartmental transfer rate constants (k 12 , k 21 ), volume of the central compartment (Vc), the volume of distribution at steady state (Vd ss ), apparent volume of distribution (Vd app ) and total body clearance (Cl) were calculated using standard formulae 17 .
Anaesthesia
During surgery the patient was monitored using the Datex AS3 system (Datex Instrumentarium Corp., Helsinki, Finland). Direct arterial blood pressure, electrocardiograph and pulse oximetry monitoring were established before induction of anaesthesia. Fentanyl 1 µg.kg -1 and midazolam 0.02 mg.kg -1 were given IV 60 seconds prior to the commencement of induction of anaesthesia with propofol 2 mg.kg -1 . Vecuronium 0.1 mg.kg -1 was administered to facilitate tracheal intubation and mechanical ventilation. Patients were ventilated to obtain an end-tidal carbon dioxide level of 35 mmHg and anaesthesia was maintained with isoflurane 1% in nitrous oxide and oxygen 35%. After general anaesthesia was induced, the patient was turned to the left lateral position and an epidural catheter placed via an 18 gauge Tuohy needle at the thoracic 11-12 interspace and advanced 5 cm inside the epidural space. Two 5 ml bolus doses of an epidural solution containing fentanyl 2 µg.ml -1 in plain bupivacaine 0.125% were administered five minutes apart, followed by a continuous infusion of the same solution at 8 ml.hr -1 (IMED Gemini PC-1, San Diego, CA). Crystalloid and colloid were administered together with 3 to 6 mg bolus doses of ephedrine to maintain mean arterial pressure within 20% of baseline values and packed cells were given intraoperatively when blood loss exceeded 10% of estimated blood volume (70 ml.kg -1 ). At the end of the operative procedure muscle relaxation was reversed with neostigmine and atropine.
Haematology
The patients included in this study were operated on by any two of four specialist surgeons attached to the Queensland Centre for Gynaecological Cancer. All Ivy bleeding time measurements were made by the same person to minimize variability and bias. Skin bleeding time 18, 19 was performed immediately before and two hours after tenoxicam administration, and at 1 and 24 hours postoperatively. Blood was also taken for measurement of haematocrit, haemoglobin, white cell count, prothrombin time, activated partial thromboplastin time, platelet count and collageninduced platelet aggregation 20 . Intraoperative blood loss was estimated from suction volume and swab weight and postoperative losses from the Bellovac ® low pressure, closed wound, drainage system (Astra Zeneca, North Ryde, N.S.W.).
Analgesia
All patients received an epidural infusion of fentanyl 2 µg.ml -1 in plain bupivacaine 0.125% commenced at 6 ml.h -1 , instituted by one investigator with pain assessment performed by another anaesthetist postoperatively. In the recovery area, the patient was asked if she required any pain relief. If yes, a 5 ml bolus of the epidural solution was administered, followed by another every 30 minutes until the patient was comfortable. The patient was then attached to an Abbott Pain Management Provider pump (Abbott Laboratories, North Chicago, IL) programmed to deliver a 5 ml bolus over 2.5 minutes on demand, with a 30 minute lockout time and an initial 6 ml.h -1 background infusion. At the discretion of the attending nursing staff, the background infusion rate was increased by 2 ml.h -1 from the baseline to a maximum of 12 ml.h -1 . If the patient required no bolus doses for two consecutive four-hour periods the background infusion was reduced by 2 ml.h -1 . Number of bolus doses and attempts, total dose, infusion rate and pump programming data were downloaded directly via the RS232 serial port to a laptop computer every 24 hours. Epidural analgesia was continued for 72 hours postoperatively in most patients with visual analog pain scores measured at rest and on leg-raising every four hours using an ungraduated, 10 cm, pain assessment slide (Abbott Laboratories, North Chicago, IL). Administration of any antiemetics (metoclopramide or prochlorperazine) and analgesics (morphine, pethidine or dextropropoxyphene) given after removal of the epidural catheter were recorded postoperatively for five days.
Statistical Analysis
With 15 patients in each group this study had at least 80% power to detect a 50% difference between the placebo (cumulative bolus of 30±14 ml; total epidural solution volume of 400±52 ml) and The plasma concentrations (Ct) as a function of time (t) for each patient were satisfactorily fitted with a biexponential expression, corresponding to a distributive phase and an elimination phase, Equation (1):
RESULTS
The patients in each group were comparable in age, height, weight, triceps skinfold, type and duration of surgery and ASA status ( Table 1) . Figure 1 illustrates the kinetic profile of tenoxicam plasma level versus time for all patients, using the mean concentration and its standard deviation for each time point. For all patients but one, the coefficients for the biexponential equation were significant (P<0.001). In the remaining patient, the coefficients were also significant at P<0.001, except for the distribution rate constant (α), which was significant at P<0.01. The derived pharmacokinetic parameters, along with their ranges and standard deviations for the 15 tenoxicam patients are reported in Table 2 .
No significant difference was found between the two groups in visual analog scores at rest and on legraising at four hours (P=0.080), 24 hours (P=0.793), or 48 hours (P=0.422) ( Figure 2 ). Repeated measures ANOVA was not applied because complete data were available only for seven subjects in the placebo group and 11 subjects in the tenoxicam group.
All patients had a functioning epidural in situ for the first 48 hours postoperatively. Compared to the placebo group, the tenoxicam group administered significantly fewer epidural bolus doses during the initial 24 hours (P=0.004) and 48 hours (P=0.010) postoperatively, but not during the 0 to 4 hour interval (P=0.089). Results for the total volumes of the bupivacaine/fentanyl administered epidurally were similar Table 3 ). The coagulation profile showed no significant differences between the placebo and tenoxicam groups in any of the measured indices, at any of the measurement times and all measured indices remained within the normal range (prothrombin time: P=0.652; active partial thromboplastin time: P=0.858; skin bleeding time: P=0.990; platelet aggregation 1.5 µg.ml -1 : P=0.576; platelet aggregation 2.0 µg.ml -1 : P=0.508; repeated measures anova) (Figure 3) . Similarly the haematological profiles for the two groups were almost identical during the first 24 hours postoperatively (Figure 4 ). The mean volume of blood lost intraoperatively, postoperative drainage during the first 24 hours and the mean volume of blood transfused (n=6) were not significantly different between the groups (Table 1) . No surgeon reported any bleeding tendency in any patient.
DISCUSSION
The pharmacokinetic disposition of tenoxicam has been extensively reported in volunteers and in patients with arthritic disease 21 but there are few reported studies in perioperative analgesia 8 . For the estimate of patient treatments, prochlorperazine 12.5 mg was taken as equivalent to metoclopramide 10 mg, pethidine 100 mg as equivalent to morphine 10 mg and paracetamol 1g as equivalent to one capsule containing dextropropoxyphene 32.5 mg and paracetamol 325 mg. P=NS across all groups (Chi-squared and Fisher's exact test) FIGURE 3: Coagulation profiles for the placebo and tenoxicam groups (median and interquartiles). There were no significant differences between the groups at any of the measurement times (repeated measures ANOVA). Tenoxicam is available for parenteral administration in New Zealand but not Australia. The intravenous route of administration was chosen for this study to ensure it reached its target site unimpeded by factors influencing absorption 8 . The mean elimination halflife (55±19 h) was at the low end of previously reported values for healthy volunteers (49 to 81h) 5 . The values for the volume of the central compartment (Vc), apparent volume of distribution (Vd app ), volume of distribution at steady state (Vd ss ) and total clearance (Cl) were all somewhat less than the corresponding values found for healthy volunteers after a 20 mg IV dose. The intercompartmental transfer rate constants were not significantly different from the literature and appear to be more precisely defined, as the standard errors are smaller 5 . The last three data points in Figure 1 demonstrate a trend which indicates that the elimination phase may be a slow redistribution phase, with the "true" elimination phase occurring even more slowly. The use of a triexponential equation could not be supported for the present data, based on the coefficients of variance for the regression parameters. Collection of plasma leveltime data over a longer time interval than the five-day duration of the present study might give further support to this suggestion. Our postoperative analgesia regimen was designed to provide consistent patient comfort and indirectly determine whether the tenoxicam induced any epidural dose-sparing effect. Visual analog scale data were not significantly different between the groups, although data were more scattered during the initial four hours postoperatively (P=0.06 at 0 to 4 hours indicating the largest VAS difference). The low dosage background infusion alone provided adequate analgesia more frequently in the tenoxicam group who self-administered significantly fewer bolus doses compared to the placebo group over 48 h (P<0.01). The placebo group, although appearing adequately analgesed by a lower background infusion at rest, required additional bolus doses during activity. A similar difference between the groups was apparent when the total volume of the bupivacaine/ fentanyl administered were compared. Post hoc, the nursing staff progress notes recorded a more consistently comfortable recovery for a longer period in the tenoxicam group. Typically, NSAIDs are introduced at the end of surgery and combined with patient-controlled opioid administration 22 . In this study, the analgesic effect of tenoxicam was observed without being perturbed by the wanted effects (euphoria) or unwanted effects (nausea and vomiting) of any IV opioid during the first 48 hours post-operatively. Furthermore antiemetic and NSAID administration during this period was very similar between the groups. Other workers investigating piroxicam showed that any between-group statistical difference was of marginal clinical significance without evidence of any epidural dose-sparing effect; however, the use of morphine may have influenced their conclusions 23 .
Patients who have undergone gynaecological oncology surgery complain of pain related to their incision and/or pelvic drainage system, the latter being very distressing if the drain compresses the pelvic neural plexus, and the pain is only effectively abolished by drain removal. In this study the same number of patients in each group underwent vertical or horizontal abdominal incision, concurrent pelvic and para-aortic lymphadenectomy and there was no between group difference in the incidence of pelvic drainage. Although there have been a number of reports of a reduction in pain and increased patient comfort following oral and minor surgery when tenoxicam has been incorporated into the postoperative care regimen [24] [25] [26] [27] , there has been no convincing report of a dramatic reduction in severe pain following major surgery 21, 28 .
Tenoxicam was chosen because of its long elimination half-life 5 , but unlike other workers who have demonstrated a decrease in supplementary analgesic requirements during the latter postoperative period 24 , we found no difference between the treatment and control group in the number of patients treated, nor the number of patient treatments after 48 hours (Table 3) . Although this study was not designed to test any pre-emptive analgesic effect 29 , the time of tenoxicam administration may be clinically important because the onset of analgesia may take 30 to 60 minutes, while the opioid-sparing effect of tenoxicam may not be apparent for four hours 12 .
There are no previous reports of tenoxicam administration to elderly patients undergoing major cancer surgery for postoperative pain relief and it was deemed prudent to administer a single 20 mg IV dose to limit the impact and incidence of any side-effects. While the optimum dose of tenoxicam for postoperative analgesia may not be known, the reported analgesic ceiling, above which increased drug dosage only results in increased toxicity without additional analgesia 30 , has again been recently confirmed by Merry and colleagues 24 . However, daily administration of tenoxicam 20 mg may improve analgesic efficacy as the intensity of the postoperative pain subsides. There were no significant side-effects and no adverse event attributable to tenoxicam at any time during the study.
Administration of a single intravenous dose of tenoxicam 20 mg two hours prior to surgery caused no objective or subjective alteration in haemostatic function or increase in blood loss in elderly women undergoing gynaecological cancer surgery. Collageninduced platelet aggregation was determined with two relatively low collagen concentrations so as not to provoke a sudden increase in intraplatelet calcium concentration and bring about the release of platelet granules without the mediation of the prostaglandin pathway 31 . Collagen-induced platelet aggregation following a single IV administration of tenoxicam 20 mg was no different from placebo and there was also no deviation outside the normal range for any of the measured haematological variables (Figures 3 and 4) . The normal bleeding times measured are therefore not unexpected, as tenoxicam only causes reversible inhibition of collagen-induced platelet aggregation at a steady-state plasma concentration of approximately 10 µg.ml -1 , without affecting the ADP-induced phase of platelet aggregation 7, 32 . The rapid redistribution of tenoxicam in our patients resulted in ineffective haemolytic tenoxicam levels within 60 minutes of IV drug administration. This absence of haemostatic impairment with tenoxicam is in contrast to a single dose of diclofenac which although having a short half-life of one to two hours, inhibits platelet cyclo-oxygenase for five to 10 hours 22 .
All our patients also received 5000U of dalteparin sodium on the evening before surgery and although low-dose heparin has no effect on bleeding time or platelet function, it does prolong clotting time and increase anti-Xa levels 33 . The minimal measured change in haemostatic parameters in our study was supported clinically by the absence of complaint by the surgeon of oozing or unsatisfactory haemostasis. The severity of intraoperative bleeding in gynaecological oncology is in the main related to surgical trauma and the nature of the cancer, unless there has been prior radiation therapy.
In conclusion, we have been able to demonstrate that tenoxicam 20 mg administered preoperatively reduced the epidural bupivacaine/fentanyl requirements during the first 48 hours following major gynaecological surgery, but despite the data trend, the possibility of a Type I error must be borne in mind in view of the small study numbers.
